On December 12, 2024, 89bio, Inc.'s Board of Directors approved the grant of restricted stock units (RSUs) for retention purposes to several key executives. Hank Mansbach, the Chief Medical Officer, Quoc Le-Nguyen, the Chief Technical Operations Officer, and Ryan Martins, the Chief Financial Officer, each received 95,000 Retention RSUs.
These Retention RSUs are structured to vest in equal semiannual installments over a 24-month period, contingent upon each recipient's continued service to the company. This compensation strategy aims to ensure the continued commitment of these vital leaders.
The retention of experienced executives is crucial for 89bio as it navigates the complex and lengthy process of late-stage clinical trials for pegozafermin in MASH and SHTG. Their ongoing leadership is essential for successful execution of clinical programs and strategic operations.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.